Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 0.61 |
| ▸ | KDR | P35968 | 3/20 | 0.61 |
| ▸ | KRAS | P01116 | 2/20 | 0.61 |
| ▸ | RAF1 | P04049 | 2/20 | 0.61 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.61 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.61 |
| ▸ | NEK7 | Q8TDX7 | 8/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4563482 | 0.90 | BRAF (0.66) | BRAFKDRKRASRAF1MAP2K2 | |
| SCHEMBL4552758 | 0.90 | BRAF (0.49) | BRAFKDRKRASRAF1MAP2K2 | |
| SCHEMBL5062481 | 0.88 | BRAF (0.61) | BRAFKDRKRASRAF1MAP2K2 | |
| SCHEMBL4565793 | 0.87 | BRAF (0.60) | BRAFKDRKRASRAF1MAP2K2 | |
| SCHEMBL5061707 | 0.87 | BRAF (0.46) | BRAFKDRKRASRAF1MAP2K2 | |
| SCHEMBL4423666 | 0.84 | BRAF (0.85) | BRAFKDRKRASRAF1MAP2K2 | |
| SCHEMBL5061678 | 0.79 | BRAF (0.54) | BRAFKDRKRASRAF1MAP2K2 | |
| SCHEMBL5057686 | 0.78 | BRAF (0.61) | BRAFKDRKRASRAF1MAP2K2 | |
| SCHEMBL4278153 | 0.77 | BRAF (0.62) | BRAFKDRKRASRAF1MAP2K2 | |
| SCHEMBL4416867 | 0.77 | BRAF (0.43) | BRAFKDRKRASRAF1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289540-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8188113-B2 | For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2063897-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| WO-2008034008-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289540-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | BRAF, PRKDC, RAF1 | BRAF 1/4885KDR 500/4885KRAS 30/4885 |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | BRAF 1/4885KDR 500/4885KRAS 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.